Abstract: In vitro metabolic behavior was investigated for two chromium tricarbonyl derivatives of the antischistosomal drug praziquantel (PZQ) with the formula ((6)-PZQ)Cr(CO)3 (1 and 2), by use of human liver microsomes. The metabolic profiles of the derivatives differ significantly. The optically pure ((6)-PZQ)Cr(CO)3 derivatives (S, Sp)-1, (R, Rp)-1, (S, Rp)-2, and (R, Sp)-2 were also prepared to assess the eudysmic ratios of 1 and 2 against Schistosoma mansoni in vitro. A strong enantioselective antischistosomal activity was observed. The R-enantiomers are highly active against adult schistosomes in vitro (IC50 0.08-0.13 M), whereas both S-enantiomers lack activity. The in vivo activity of 1 and 2 was then studied in mice harboring a chronic S. mansoni infection. A single dose of 1 and 2 (400 mg/kg) resulted in low worm burden reductions of 24% and 29% (p > 0.05). DOI: https://doi.org/10.1021/jm401287m
Introduction.
Schistosomiasis is the second most prevalent parasitic disease in the world after malaria with 207 million people infected each year. Surprisingly there is only one available drug on the market to treat the disease, Praziquantel (PZQ) (Figure 1 ). 1, 2 Despite the identification of various lead antischistosomal compounds, no new drugs have entered the market since the development of PZQ in 1970s. 3 Reliance on a single drug is dangerous and reduced susceptibility of Schistosoma mansoni (S. mansoni) to PZQ has already been noted in the field. [4] [5] [6] The important limitations of PZQ make the situation even more precarious. PZQ has low metabolic stability in vivo 7, 8 and lacks activity against the juvenile stage of Schistosoma. 9 Taken together, these facts are a strong indication that novel drugs to treat schistosomiasis are required. With this in mind, our groups have recently embarked on a project to study the potential of organometallic-containing PZQ derivatives as antischistosomal agents. This concept originates from the pioneering work of Jaouen, Biot and co-workers on organometallic derivatives of the anticancer agent Tamoxifen (Ferrocifens) and the antimalarial Chloroquine (Ferroquine). 10, 11 For both Ferrocifens and
Ferroquine, the addition of a ferrocenyl moiety into the known organic drug allowed the addition of novel modes of action to the parent compounds. 12, 13 Encouraged by these results, we investigated the antischistosomal activity of 18 ferrocenyl derivatives of PZQ. 14 Unfortunately, only moderate in vitro activity could be determined.
important to assess the metabolic fate of a drug candidate. As a continuation of our development on the (η 6 -PZQ)Cr(CO) 3 derivatives, we present herein the in-depth in vitro metabolic behavior of these chromium derivatives as well as their antischistosomal activity in mice infected with adult S. mansoni. Importantly, we could demonstrate, by preparing optically active (S, Sp)-1, (R, 
Rp)-1, (S,
Rp
Results and Discussion.
In Vitro Metabolism Studies. In order to gain insight into the metabolic fate of the racemic (η 6 -PZQ)Cr(CO) 3 derivatives 1 and 2, we investigated their in vitro metabolic behavior using human liver microsomes. Accordingly 1, 2 and PZQ were incubated with human liver microsomes in the presence of NADPH at 37 °C (see SI for details). Diazepam which is (known to be stable in human liver microsomes) was used as a positive control. After incubation, compounds were immediately extracted with dichloromethane which was evaporated to provide residues that were analyzed using LC-MS. The metabolites were identified by comparing the differences in the respective m/z values in MS spectra with those determined for the parent compound (1 or 2) and PZQ (see Table S1 , S2 for details). The identities of the major metabolites were further confirmed by comparing the retention time in the UV trace and the mass spectrum from the LC-
MS analysis of authentic samples (vide infra).
Semi-quantitative analysis of the ratio of parent compound and different metabolites present in the mixture after post incubation with human liver microsomes was achieved by comparing the areas under the respective peaks of different compounds visible in the UV traces of the LC analysis (see Table S3 for details).
In the case of 1, formation of two major and three minor metabolites was observed (see Figure 2 and The other three minor metabolites were detected at retention times of 10.1 (1.M3), 10.5 (1.M4) and 10.9 (1.M5) minutes ( Figure 2 and Table S1 ). Metabolites 1.M3 and 1.M4 have a similar mass spectrum with an intense peak at m/z = 465.1 (Table S1 ) that matches well the protonated adduct of mono-hydroxylated species of made to confirm the structure of these metabolites. The hydroxylation of 1, most likely, occurs in the cyclohexane ring or at the tetrahydroisoquinoline part. The minor metabolite 1.M5 also has a similar mass spectrum pattern to PZQ-OH with a central peak at m/z = 329.2, which corresponds to another mono-hydroxylated derivative of PZQ (see Table S1 ). Although we could confirm, by comparing the UV traces from LC-MS analysis, that 1.M5 is not the trans-4-PZQ-OH ( Figure S1 in SI), we could not structurally characterize 1.M5 due to a lack of any standard matching compound. However, as reported earlier, the hydroxylation in 1.M5 is expected to occur either at the tetrahydroquinoline part or at the aromatic ring of PZQ.
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A plausible metabolic profile of 1 explaining the possible routes of formation of metabolites is presented in Scheme 1(a). Metabolism rate and profile data were obtained for compound 2 that were significantly different to those obtained for 1 ( Figure 2 , right, c) and d) and Table S2 ). A metabolic profile of 2 is schematically presented in Scheme 1. Only a trace amount of 2 was present in the microsomes/NADPH mixture after 2.5 h (Table S3 ). The most abundant metabolite 2.M1 (ca. was also observed and these were characterized from their corresponding UV traces and ESI-MS spectra (see Figure S2 and Table S2 in SI).
The metabolism study of 1 and 2 was authenticated by carrying out a metabolic study on PZQ itself using the same assay as for 1 and 2 and by further comparison with previously reported results. [17] [18] [19] [20] [21] [22] As shown in Figure S3 in SI, PZQ was exclusively metabolized to its monohydroxylated species 1.M2 (cis-4-PZQ-OH) and 1.M5 (an unidentified mono-hydroxylated derivative). This observation is in good agreement with reports described earlier. 17, 22 Formation of a trace amount of trans-4-PZQ-OH was also observed.
Of note, using the experimental conditions and LC-MS setup reported in this study, we did not observe the presence of any dehydrogenated metabolites for PZQ, 1 and 2, as previously reported for PZQ by Alnouti, Kiec-Kononowicz and co-workers using different analytical techniques and/or a slightly different in vitro model (human cytochrome P-450 3A4 expressed in Escherichia coli and Saccharomyces cerevisiae instead of microsomes).
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Although we were unable to detect any of these metabolites, the possibility of their formation cannot be completely ruled out. One can speculate that the dehydrogenated compounds could be formed as minor metabolites that co-elute with a major metabolite and that the MS only detects the more abundant component present in the mixture. 
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Scheme 2. Synthesis of 3 and optically pure (η 6 -PZQ)Cr(CO) 3 derivatives. Note that Praziquanamine, 3 and Iso-3 are racemates.
In Vitro Antischistosomal Activity Studies of Optically pure (η 6 -PZQ)Cr(CO) 3 derivatives and selected metabolites of 1 and 2. In order to assess if only one enantiomer of compounds 1 and 2 were active against S. mansoni (as is the case for PZQ) the optically pure (η 6 -PZQ)Cr(CO) 3 derivatives were prepared using a similar synthetic pathway as for rac-1 and 2 (see Scheme 2 for details). In Vivo Antischistosomal Activity Studies. To assess the in vivo potential of the chromium tricarbonyl derivatives, 1 and 2 were given orally to mice harboring a chronic S. mansoni infection. The racemate mixtures of 1 and 2 were given to mice for comparison purposes with PZQ, which is itself given as a racemate. The results are summarized in Table 2 . Treatment of mice at a single dose of 400 mg/kg of 1 and 2 resulted in low worm burden reductions of 24 and 29 % (p>0.05), respectively. In the treatment group of compound 1, two mice died one day posttreatment whereas one of the mice treated with 2 died 4 days post-treatment. For comparison, at this dose (400 mg/kg) worm burden reductions of 96% are achieved with PZQ. 26 The toxicity observed was unexpected as 1 and 2 did not present any cytotoxicity on the non-cancerous cell line MRC-5 up to 100 µM compound concentration. 15 The low in vivo activity observed can be attributed to the metabolic lability of 1 and 2 resulting in less active metabolites (Table 2 ). It is interesting that both compounds exert a similar low in vivo activity despite compound 1 being metabolized to PZQ. However, since S. mansoni live in the mesenteric veins they might not be exposed to PZQ before it is metabolised in the liver through first-pass. It can also be hypothesized that the relatively low in vivo activity observed is due to protein binding or distribution problems. Further experiments outside the scope of this article should be undertaken to evaluate these assumptions. 
Conclusions
Taken together, the low in vivo antischistosomal activity as well as toxicity observed for 1 and 2 compared to PZQ contrast with the remarkable in vitro results previously described 15 and further emphasize the necessity for in vivo confirmation of in vitro hits. It is important to note that the toxicity observed cannot be at least fully attributed to chromium toxicity but might instead have been caused by the schistosome infection. The amount of chromium given to the mice (400 mg/kg of (η 6 -PZQ)Cr(CO) 3 derivatives), assuming a full release of chromium from 1 and 2 as well as the oxidation of Cr(0) to the more in vivo stable Cr(III), is insufficient to kill mice: the LD 50 values of Cr(III) salts are 3.2-15 g/kg, when administered orally in rats. 27 Of note, Cr(III) has even been used as an antidiabetic agent. 28 In summary in this study we have demonstrated, using human liver microsomes, that two (η 6 -PZQ)Cr(CO) 3 derivatives, which were previously shown to have in vitro activity against S.
mansoni comparable to PZQ, were metabolically labile. Clear differences in the rate of metabolism and identity of the metabolites produced were observed between 1 and 2. Indeed, while 1 was metabolized slowly and produced PZQ and PZQ-OH as the most abundant metabolites, 2 was mostly metabolized to 3 and to a lesser extent to PZQ and PZQ-OH.
Importantly, an enantioselective in vitro antischistosomal activity comparable to PZQ itself was determined for the organometallic compounds 1 and 2. These results are a good indication that the active form of 1 and 2 bind to the same target(s) as PZQ. Finally, in vivo experiments demonstrated that low worm burden reductions of 24 and 29 % (p>0.05) were obtained when a single dose of 1 and 2 (400 mg/kg) were given to mice harboring a chronic S. mansoni infection.
Overall the results presented herein will give valuable information to the rapidly growing field of medicinal organometallic chemistry field.
Dyson in a recent review about organometallic anticancer compounds, there is an important lack of published in vivo studies on non-radioactive bioorganometallic compounds. 30 We therefore do believe that the work presented in this study will help to fill this important gap and hopefully allow more organometallic compounds to become part of drug research and development.
Experimental section.
Materials. All chemicals were of reagent grade quality or better, obtained from commercial suppliers and used without further purification. Solvents were used as received or dried over molecular sieves. All preparations were carried out using standard Schlenk techniques. 1, 2,
praziquanamine, trans-4-PZQ-OH and cis-4-PZQ-OH, R-PZQ and S-PZQ were prepared
following standard literature procedures. 15, 16, 24, 31, 32 The optically pure four (η 6 -PZQ)Cr(CO) 3 derivatives were prepared using R-PZQ and S-PZQ following a procedure reported for synthesis of 1 and 2. 15 The purities of compounds ( mansoni infection (49 days post-infection) were treated orally with the test drugs using single oral doses (400 mg/kg). Untreated mice (n=9) served as controls. Fourteen days post-treatment animals were sacrificed by the CO 2 method and dissected. Worms were sexed and counted. 34 Worm burdens of treated mice were compared to control animals and reductions of worm burden calculated. To compare the medians of the responses between the treatment and control groups the Kruskal-Wallis test was utilized. A difference in median was considered to be significant at a significance level of 5%.
Determination of in vitro activity against Schistosoma mansoni.
Schistosomes were cultured in RPMI 1640 culture medium (supplemented with 5% inactivated fetal calf serum (iFCS) and 100 U/mL penicillin as well as 100 µg/mL streptomycin (Invitrogen, Carlsbad, USA)) at 37 °C in an atmosphere of 5% CO 2 . All compounds of interest were tested at a concentration range of 0.11 -30 µg/ml (0.11, 0.33, 1.1, 3.3, 10 and 30 µg/ml), using DMSO stock solutions (conc. 10 mg/ml; final concentration of DMSO: 0.3 %) diluted in supplemented RPMI 1640 medium within 24 flat bottom well plates (BD Falcon, USA) with a final volume of 2 ml per well. 35 Three worms of both sexes, were placed into each well. Wells with the highest concentration of DMSO in medium served as controls. Praziquantel served as positive control.
Phenotypes were monitored after 72 h using the motility scale described by Ramirez et al. 36 www.gassergroup.com.
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